$ALLO
Allogene Therapeutics, Inc. Stock $allo

$allo Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000173728724000021 Filed on March 14, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$22.00K	$95.00K	$95.00K
YoY Change	-57.69%	102.13%	-60.91%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$17.27M	$71.67M	$71.67M
YoY Change	-8.56%	241.27%	-9.62%
% of Gross Profit
Research & Development	$52.26M	$242.9M	$242.9M
YoY Change	-34.87%	222.09%	-5.25%
% of Gross Profit
Depreciation & Amortization	$3.555M	$3.477M	$14.20M
YoY Change	1.37%	13.33%	-0.71%
% of Gross Profit
Operating Expenses	$69.53M	$314.6M	$314.6M
YoY Change	-29.86%	226.26%	-6.29%
Operating Profit	-$69.50M		-$327.7M
YoY Change	-29.84%		-2.3%
Interest Expense	$5.433M	$18.31M	$18.31M
YoY Change	163.87%	564.02%	300.94%
% of Operating Profit
Other Income/Expense, Net	$4.504M	-$17.84M	-$17.84M
YoY Change	1130.6%	1350.0%	-733.12%
Pretax Income	-$65.00M	-$327.3M	-$327.3M
YoY Change	-34.15%	245.05%	-1.61%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$65.00M	-$327.3M	-$327.3M
YoY Change	-34.15%	245.05%	-1.61%
Net Earnings / Revenue	-295454.55%	-344489.47%	-344489.47%
Basic Earnings Per Share	-$0.38		-$2.09
Diluted Earnings Per Share	-$0.38	-$2.09	-$2.09
COMMON SHARES
Basic Shares Outstanding	169.1M shares	168.3M shares	156.9M shares
Diluted Shares Outstanding	169.1M shares		156.9M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$384.9M	$448.7M	$448.7M
YoY Change	-18.33%	-13.27%	-13.27%
Cash & Equivalents	$51.04M	$83.16M	$83.16M
Short-Term Investments	$333.8M	$365.5M	$365.5M
Other Short-Term Assets	$10.50M	$10.42M	$8.718M
YoY Change	2.57%	-9.44%	-10.16%
Inventory
Prepaid Expenses
Receivables			$1.700M
Other Receivables			$0.00
Total Short-Term Assets	$395.4M	$459.1M	$459.1M
YoY Change	-17.88%	-13.18%	-13.18%
LONG-TERM ASSETS
Property, Plant & Equipment	$95.93M	$163.2M	$163.2M
YoY Change	-12.67%	44.61%	-16.93%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$15.12M	$3.645M	$3.645M
YoY Change	-71.95%	-94.94%	-94.94%
Other Assets	$5.159M	$16.90M	$16.90M
YoY Change	-45.05%	76.66%	-14.91%
Total Long-Term Assets	$191.0M	$183.7M	$183.7M
YoY Change	-28.04%	-36.26%	-36.26%
TOTAL ASSETS
Total Short-Term Assets	$395.4M	$459.1M	$459.1M
Total Long-Term Assets	$191.0M	$183.7M	$183.7M
Total Assets	$586.4M	$642.8M	$642.8M
YoY Change	-21.49%	-21.32%	-21.32%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.779M	$5.897M	$5.897M
YoY Change	-60.65%	-57.54%	-57.54%
Accrued Expenses	$25.03M	$31.10M	$31.10M
YoY Change	-43.91%	-21.76%	-21.76%
Deferred Revenue	$86.00K	$86.00K
YoY Change	-68.5%	-90.28%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$30.89M	$37.08M	$37.08M
YoY Change	-48.15%	-31.99%	-31.99%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$5.173M	$93.53M	$93.53M
YoY Change	242.58%	5860.8%	-3.27%
Total Long-Term Liabilities	$5.173M	$93.53M	$93.53M
YoY Change	242.58%	5860.8%	-3.27%
TOTAL LIABILITIES
Total Short-Term Liabilities	$30.89M	$37.08M	$37.08M
Total Long-Term Liabilities	$5.173M	$93.53M	$93.53M
Total Liabilities	$125.0M	$130.6M	$130.6M
YoY Change	-19.16%	-13.63%	-13.63%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.627B	-$1.562B
YoY Change	21.92%	26.4%
Common Stock	$2.090B	$2.075B
YoY Change	8.1%	8.56%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$461.4M	$512.2M	$512.2M
YoY Change
Total Liabilities & Shareholders Equity	$586.4M	$642.8M	$642.8M
YoY Change	-21.49%	-21.32%	-21.32%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$65.00M	-$327.3M	-$327.3M
YoY Change	-34.15%	245.05%	-1.61%
Depreciation, Depletion And Amortization	$3.555M	$3.477M	$14.20M
YoY Change	1.37%	13.33%	-0.71%
Cash From Operating Activities	-$55.90M	-$53.71M	-$237.7M
YoY Change	-16.12%	-13.51%	7.81%
INVESTING ACTIVITIES
Capital Expenditures	$8.000K	$181.0K	$1.516M
YoY Change	-99.23%	-89.3%	-70.8%
Acquisitions
YoY Change
Other Investing Activities	$22.14M	$67.64M	$164.8M
YoY Change	-80.57%	31.88%	48.01%
Cash From Investing Activities	$22.13M	$67.46M	$163.3M
YoY Change	-80.4%	36.02%	53.82%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$95.70M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$1.650M	155.0K	95.70M
YoY Change	-4.68%	236.96%	3143.9%
NET CHANGE
Cash From Operating Activities	-$55.90M	-53.71M	-237.7M
Cash From Investing Activities	$22.13M	67.46M	163.3M
Cash From Financing Activities	$1.650M	155.0K	95.70M
Net Change In Cash	-$32.12M	13.91M	21.25M
YoY Change	-166.87%	-211.69%	-119.07%
FREE CASH FLOW
Cash From Operating Activities	-$55.90M	-$53.71M	-$237.7M
Capital Expenditures	$8.000K	$181.0K	$1.516M
Free Cash Flow	-$55.91M	-$53.89M	-$239.2M
YoY Change	-17.39%	-15.52%	6.0%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	us-gaap	Operating Lease Expense OperatingLeaseExpense	642000	usd
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.12
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001737287
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2018Q4	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.1905
CY2023Q4	us-gaap	Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss Statement Of Financial Position Extensible List DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#PrepaidExpenseAndOtherAssetsCurrent
CY2022Q4	us-gaap	Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss Statement Of Financial Position Extensible List DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#PrepaidExpenseAndOtherAssetsCurrent
CY2022Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://allogene.com/20231231#AccruedAndOtherLiabilitiesCurrent
CY2023Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://allogene.com/20231231#AccruedAndOtherLiabilitiesCurrent
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-38693
CY2023	dei	Entity File Number EntityFileNumber	001-38693
CY2023	dei	Entity Registrant Name EntityRegistrantName	Allogene Therapeutics, Inc.
CY2023	dei	Entity Registrant Name EntityRegistrantName	Allogene Therapeutics, Inc.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	82-3562771
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	82-3562771
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	210 East Grand Avenue
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	210 East Grand Avenue
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	South San Francisco
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	South San Francisco
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94080
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94080
CY2023	dei	City Area Code CityAreaCode	650
CY2023	dei	City Area Code CityAreaCode	650
CY2023	dei	Local Phone Number LocalPhoneNumber	457-2700
CY2023	dei	Local Phone Number LocalPhoneNumber	457-2700
CY2023	dei	Security12b Title Security12bTitle	Common Stock, Par Value $0.001 Per Share
CY2023	dei	Security12b Title Security12bTitle	Common Stock, Par Value $0.001 Per Share
CY2023	dei	Trading Symbol TradingSymbol	ALLO
CY2023	dei	Trading Symbol TradingSymbol	ALLO
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	true
CY2023	dei	Document Fin Stmt Restatement Recovery Analysis Flag DocumentFinStmtRestatementRecoveryAnalysisFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	557000000	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	169091992	shares
CY2023	dei	Auditor Firm AuditorFirmId	42
CY2023	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2023	dei	Auditor Location AuditorLocation	San Mateo, California
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	83155000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	61904000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	365542000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	455416000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	10418000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	11504000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	459115000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	528824000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	0	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	59151000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	63703000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	83592000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	99478000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	112839000	usd
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	10292000	usd
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	10292000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	6604000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	9564000	usd
CY2023Q4	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	3645000	usd
CY2022Q4	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	17317000	usd
CY2023Q4	us-gaap	Assets Assets	642837000	usd
CY2022Q4	us-gaap	Assets Assets	821579000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	5897000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	13890000	usd
CY2023Q4	allo	Accrued And Other Liabilities Current AccruedAndOtherLiabilitiesCurrent	31096000	usd
CY2022Q4	allo	Accrued And Other Liabilities Current AccruedAndOtherLiabilitiesCurrent	39743000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	86000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	95000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	37079000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	53728000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	88346000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	95122000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	5179000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	5847000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	130604000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	154697000	usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	168642238	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	168642238	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	144438304	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	144438304	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	169000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	144000	usd
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	2075252000	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1911632000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1562233000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1234968000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-955000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-9926000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	512233000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	666882000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	642837000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	821579000	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	95000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	156000	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	114089000	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	242914000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	256387000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	220176000	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	71673000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	79305000	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	74105000	usd
CY2023	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	13245000	usd
CY2022	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
CY2021	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	327832000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	335692000	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	294281000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-327737000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-335536000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-180192000	usd
CY2023	us-gaap	Interest And Other Income InterestAndOtherIncome	18307000	usd
CY2022	us-gaap	Interest And Other Income InterestAndOtherIncome	4566000	usd
CY2021	us-gaap	Interest And Other Income InterestAndOtherIncome	1714000	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-17835000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-9444000	usd
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-3573000	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	472000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-4878000	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1859000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-327265000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-340414000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-182051000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	8971000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-7359000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-2835000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-318294000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-347773000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-184886000	usd
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.09
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.09
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.38
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.38
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.34
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.34
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	156931778	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	143147165	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	143147165	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	135820386	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	135820386	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	1013457000	usd
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	8346000	usd
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	3848000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	80818000	usd
CY2021	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	3617000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-182051000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-2835000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	925200000	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	489000	usd
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	2905000	usd
CY2022	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-21000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	83600000	usd
CY2022	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	2461000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-340414000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-7359000	usd
CY2023	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1700000	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	91112000	usd
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2087000	usd
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	1999000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	65951000	usd
CY2023	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	2496000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-327265000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	8971000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	512233000	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-327265000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-340414000	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-182051000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	65951000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	83600000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	80818000	usd
CY2023	us-gaap	Depreciation Depreciation	14199000	usd
CY2022	us-gaap	Depreciation Depreciation	14295000	usd
CY2021	us-gaap	Depreciation Depreciation	10454000	usd
CY2023	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	6809000	usd
CY2022	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	-2891000	usd
CY2021	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	-6955000	usd
CY2023	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	13245000	usd
CY2022	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
CY2021	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
CY2023	us-gaap	Equity Method Investment Other Than Temporary Impairment EquityMethodInvestmentOtherThanTemporaryImpairment	7000000	usd
CY2022	us-gaap	Equity Method Investment Other Than Temporary Impairment EquityMethodInvestmentOtherThanTemporaryImpairment	0	usd
CY2021	us-gaap	Equity Method Investment Other Than Temporary Impairment EquityMethodInvestmentOtherThanTemporaryImpairment	0	usd
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	2433000	usd
CY2021	us-gaap	Operating Lease Expense OperatingLeaseExpense	2611000	usd
CY2023	allo	Noncash Collaboration Revenue NoncashCollaborationRevenue	63000	usd
CY2022	allo	Noncash Collaboration Revenue NoncashCollaborationRevenue	104000	usd
CY2021	allo	Noncash Collaboration Revenue NoncashCollaborationRevenue	75740000	usd
CY2023	allo	Gain Loss From Equity Method Investment GainLossFromEquityMethodInvestment	-10672000	usd
CY2022	allo	Gain Loss From Equity Method Investment GainLossFromEquityMethodInvestment	-12883000	usd
CY2021	allo	Gain Loss From Equity Method Investment GainLossFromEquityMethodInvestment	-4090000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1086000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-2517000	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-3199000	usd
CY2023	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	1455000	usd
CY2022	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	3334000	usd
CY2021	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	646000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-7502000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	4868000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-767000	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-6820000	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	1749000	usd
CY2021	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	3652000	usd
CY2023	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-3000	usd
CY2021	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-38297000	usd
CY2023	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-611000	usd
CY2022	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-1882000	usd
CY2021	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	910000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-237733000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-220519000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1516000	usd
CY2023	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	0	usd
CY2022	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	0	usd
CY2021	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	17710000	usd
CY2023	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	5623000	usd
CY2022	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	0	usd
CY2021	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	0	usd
CY2023	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	597811000	usd
CY2022	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	359459000	usd
CY2021	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	728394000	usd
CY2023	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	438629000	usd
CY2022	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	248109000	usd
CY2021	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	525583000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	163289000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	106159000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	163655000	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	91112000	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
CY2023	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	2087000	usd
CY2022	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	489000	usd
CY2021	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	8346000	usd
CY2023	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	2496000	usd
CY2022	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	2461000	usd
CY2021	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	3617000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	95695000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2950000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	11963000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	21251000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-111410000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-9194000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	72196000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	183606000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	192800000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	93447000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	72196000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	183606000	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	31361000	usd
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	20079000	usd
CY2023	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	usd
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	678000	usd
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1725000	usd
CY2023	allo	Capitalized Costs CapitalizedCosts	0	usd
CY2022	allo	Capitalized Costs CapitalizedCosts	415000	usd
CY2021	allo	Capitalized Costs CapitalizedCosts	0	usd
CY2023	allo	Noncash Or Part Noncash Deferred Revenue And Other Long Term Liabilities NoncashOrPartNoncashDeferredRevenueAndOtherLongTermLiabilities	3094000	usd
CY2022	allo	Noncash Or Part Noncash Deferred Revenue And Other Long Term Liabilities NoncashOrPartNoncashDeferredRevenueAndOtherLongTermLiabilities	3157000	usd
CY2021	allo	Noncash Or Part Noncash Deferred Revenue And Other Long Term Liabilities NoncashOrPartNoncashDeferredRevenueAndOtherLongTermLiabilities	3260000	usd
CY2023	us-gaap	Payments For Leasing Costs Commissions And Tenant Improvements PaymentsForLeasingCostsCommissionsAndTenantImprovements	12049000	usd
CY2022	us-gaap	Payments For Leasing Costs Commissions And Tenant Improvements PaymentsForLeasingCostsCommissionsAndTenantImprovements	9540000	usd
CY2021	us-gaap	Payments For Leasing Costs Commissions And Tenant Improvements PaymentsForLeasingCostsCommissionsAndTenantImprovements	6013000	usd
CY2023	us-gaap	Payments For Proceeds From Tenant Allowance PaymentsForProceedsFromTenantAllowance	0	usd
CY2022	us-gaap	Payments For Proceeds From Tenant Allowance PaymentsForProceedsFromTenantAllowance	325000	usd
CY2021	us-gaap	Payments For Proceeds From Tenant Allowance PaymentsForProceedsFromTenantAllowance	1111000	usd
CY2019Q4	allo	Stock Issuance Maximum Compensation Due To Third Party Percent StockIssuanceMaximumCompensationDueToThirdPartyPercent	0.030
CY2020Q2	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	13457447	shares
CY2020Q2	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	47.00
CY2020Q2	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	632500000	usd
CY2020Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	595700000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	448700000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1562200000	usd
CY2023	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restatement of financial statements</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As described further in Note 6 and Note 8, on December 14, 2020, the Company entered into an Exclusive License Agreement (License Agreement) with Allogene Overland Biopharm (CY) Limited (Allogene Overland), a joint venture established by the Company and Overland Pharmaceuticals (CY) Inc. (Overland) pursuant to a Share Purchase Agreement </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(Share Purchase Agreement), dated December 14, 2020, for the purpose of developing, manufacturing and commercializing certain allogeneic CAR T cell therapies for patients in greater China, Taiwan, South Korea and Singapore, which resulted in the Company acquiring shares of Allogene Overland’s Seed Preferred Stock (Seed Preferred Shares) representing a 49% ownership interest in exchange for entering into a License Agreement.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In 2023, the Company re-evaluated its application of ASC Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Revenue from Contracts with Customers (ASC 606) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">and ASC Topic 323, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Investments - Equity Method and Joint ventures (ASC 323) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">to its License Agreement and Share Purchase Agreement with Allogene Overland. Upon reassessment, the Company has determined the 49% of Allogene Overland's outstanding Seed Preferred Shares received as a partial consideration for the License Agreement should be initially measured at fair value of $79.0 million rather than the zero carryover basis originally attributed to the Seed Preferred Shares. The initial transaction price to determine revenue related to the License Agreement was revised to include the fair value of the Seed Preferred Shares of $79.0 million and was allocated to the identified performance obligations based on their estimated standalone selling price. Additional revisions were made in the year ended December 31, 2020 whereby, on the date when the Seed Preferred Shares were received, the Company recorded as "Other expenses" in its consolidated statements of operations and comprehensive loss the basis difference of $67.5 million between the fair value of the Seed Preferred Shares of $79.0 million and the amount of the Company's underlying equity in net assets of Allogene Overland of $11.5 million and reduced the carrying value of the Seed Preferred Shares to $11.5 million. In the year ended December 31, 2021, the collaboration revenue increased by $75.6 million and the remaining transaction price of $3.4 million will impact subsequent future periods when related performance obligations are satisfied. Further, the Company recorded its share of net losses of Allogene Overland in each reporting period and reduced the carrying value of the Seed Preferred Shares. Refer to the Impact of restatement section below which describes detailed impact of the restatement for all the periods presented.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The error resulted in an understatement of collaboration revenue and other expenses in the consolidated statements of operations and comprehensive loss for the years ended December 31, 2022, 2021 and 2020, and an understatement of deferred revenue and equity method investment in the consolidated balance sheets as of December 31, 2022 and 2021. These annual periods were restated in the Amendment No. 1 to the Annual Report on Form 10-K/A for the year ended December 31, 2022 filed with the Securities and Exchange Commission (the SEC) on March 14, 2024. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The consolidated financial statements (as restated) also include adjustments to correct certain other previously identified misstatements relating to prior periods that the Company had determined to be immaterial, both individually and in aggregate, with a decrease in other expenses of $0.7 million for the year ended December 31, 2021 and an increase in other expenses of $2.0 million for the year ended December 31, 2022 in the consolidated statements of operations and comprehensive loss.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Impact of restatement</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See below for reconciliation from the previously reported to the restated amounts in the consolidated statements of operations and comprehensive loss for the years ended December 31, 2022 and 2021, and in the consolidated balance sheets as of December 31, 2022. The previously reported amounts were derived from the Company's Annual Report on Form 10-K for the year ended December 31, 2022 filed with the SEC on February 28, 2023 (Original Report). These amounts are labeled as "As Previously Reported" in the tables below. The amounts labeled "Restatement Adjustment" represent the effects of this restatement described above.</span></div>
CY2022Q4	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	17317000	usd
CY2022Q4	us-gaap	Assets Assets	821579000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	95000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	53728000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	5847000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	154697000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1234968000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	666882000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	821579000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	156000	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	114089000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	256387000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	220176000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	79305000	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	74105000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	335692000	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	294281000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-335536000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-180192000	usd
CY2022	us-gaap	Interest And Other Income InterestAndOtherIncome	4566000	usd
CY2021	us-gaap	Interest And Other Income InterestAndOtherIncome	1714000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-9444000	usd
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-3573000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-4878000	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1859000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-340414000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-182051000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax	-7359000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax	-2835000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-347773000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-184886000	usd
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.38
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.38
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.34
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.34
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	143147165	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	143147165	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	135820386	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	135820386	shares
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-340414000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-182051000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1234968000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-894554000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	666882000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	925200000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-340414000	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-182051000	usd
CY2022	allo	Noncash Collaboration Revenue NoncashCollaborationRevenue	104000	usd
CY2021	allo	Noncash Collaboration Revenue NoncashCollaborationRevenue	75740000	usd
CY2022	allo	Gain Loss From Equity Method Investment GainLossFromEquityMethodInvestment	-12883000	usd
CY2021	allo	Gain Loss From Equity Method Investment GainLossFromEquityMethodInvestment	-4090000	usd
CY2022	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-21000	usd
CY2021	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-38297000	usd
CY2022	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-1882000	usd
CY2021	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	910000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-220519000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-184812000	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions made in the accompanying consolidated financial statements include but are not </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">limited to the fair value of common stock, the fair value of stock options, the fair value of investments, income tax uncertainties, and certain accruals. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances change. Actual results could differ from those estimates.</span></div>
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit and other Risks and Uncertainties</span></div><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of cash and cash equivalents and investments. The primary objectives for the Company’s investment portfolio are the preservation of capital and the maintenance of liquidity. The Company does not enter into any investment transaction for trading or speculative purposes.</span></div><div style="margin-top:12pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s investment policy limits investments to certain types of instruments such as certificates of deposit, commercial paper, money market instruments, obligations issued by the U.S. government and U.S. government agencies as well as corporate debt securities, and places restrictions on maturities and concentration by type and issuer. The Company maintains cash balances in excess of amounts insured by the FDIC and concentrated within a limited number of financial institutions. The accounts are monitored by management and management believes that the financial institutions are financially sound, and, accordingly, minimal credit risk exists with respect to these financial institutions. As of December 31, 2023 and 2022, the Company has not experienced any significant credit losses in such accounts or investments.</span></div><div style="margin-top:12pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to a number of risks common for early-stage biopharmaceutical companies including, but not limited to, the ability to achieve any clinical or commercial success of its product candidates, ability to obtain regulatory approval of its product candidates, the need for substantial additional financing to achieve its goals, uncertainty of broad adoption of its approved products, if any, by physicians and patients, significant competition, dependency on the Company's contract manufacturing organization, and ability to manufacture.</span></div>
CY2023	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2023	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	13200000	usd
CY2021	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
CY2022	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
CY2023Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	0	usd
CY2022Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	0	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	444589000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	245000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	756000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	444078000	usd
CY2023Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	78536000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	365542000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	0	usd
CY2023Q4	allo	Cash Equivalents And Short Term Investments CashEquivalentsAndShortTermInvestments	444078000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	535809000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	30000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	9512000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	526327000	usd
CY2022Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	11760000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	455416000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	59151000	usd
CY2022Q4	allo	Cash Equivalents And Short Term Investments CashEquivalentsAndShortTermInvestments	526327000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	365542000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	456497000	usd
CY2023Q4	allo	Debt Securities Available For Sale Fair Value Maturity Allocated And Single Maturity Date Year One Through Two DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearOneThroughTwo	0	usd
CY2022Q4	allo	Debt Securities Available For Sale Fair Value Maturity Allocated And Single Maturity Date Year One Through Two DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearOneThroughTwo	59151000	usd
CY2023Q4	allo	Debt Securities Available For Sale Fair Value Maturity Allocated And Single Maturity Date Year Three DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearThree	0	usd
CY2022Q4	allo	Debt Securities Available For Sale Fair Value Maturity Allocated And Single Maturity Date Year Three DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateYearThree	0	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Maturities Without Single Maturity Date Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue	78536000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities Without Single Maturity Date Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue	10679000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	444078000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	526327000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Term DebtSecuritiesAvailableForSaleTerm	P1Y
CY2022Q4	us-gaap	Debt Securities Available For Sale Term DebtSecuritiesAvailableForSaleTerm	P1Y
CY2023	us-gaap	Debt Securities Available For Sale Realized Loss DebtSecuritiesAvailableForSaleRealizedLoss	1000000	usd
CY2021	us-gaap	Debt Securities Available For Sale Realized Loss DebtSecuritiesAvailableForSaleRealizedLoss	0	usd
CY2022	us-gaap	Debt Securities Available For Sale Realized Loss DebtSecuritiesAvailableForSaleRealizedLoss	0	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	48400000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	329400000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss	1700000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss	1800000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	150562000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	149724000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	51084000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	36885000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	99478000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	112839000	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	14200000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	14300000	usd
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	10500000	usd
CY2023	us-gaap	Property Plant And Equipment Disposals PropertyPlantAndEquipmentDisposals	100000	usd
CY2022	us-gaap	Property Plant And Equipment Disposals PropertyPlantAndEquipmentDisposals	100000	usd
CY2021	us-gaap	Property Plant And Equipment Disposals PropertyPlantAndEquipmentDisposals	0	usd
CY2023	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2023	us-gaap	Sublease Income SubleaseIncome	22700000	usd
CY2023	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	13200000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	12665000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	17935000	usd
CY2023Q4	allo	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	9315000	usd
CY2022Q4	allo	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	11790000	usd
CY2023Q4	allo	Accrued Lease Liability AccruedLeaseLiability	6775000	usd
CY2022Q4	allo	Accrued Lease Liability AccruedLeaseLiability	6002000	usd
CY2023Q4	allo	Unvested Shares Liabilities Current UnvestedSharesLiabilitiesCurrent	532000	usd
CY2022Q4	allo	Unvested Shares Liabilities Current UnvestedSharesLiabilitiesCurrent	1898000	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1809000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	2118000	usd
CY2023Q4	allo	Accrued And Other Liabilities Current AccruedAndOtherLiabilitiesCurrent	31096000	usd
CY2022Q4	allo	Accrued And Other Liabilities Current AccruedAndOtherLiabilitiesCurrent	39743000	usd
CY2018Q3	allo	Area Of New Office Building AreaOfNewOfficeBuilding	68000	sqft
CY2018Q3	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P127M
CY2018Q3	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P7Y
CY2023Q4	us-gaap	Tenant Improvements TenantImprovements	5000000	usd
CY2021Q4	allo	Additional Area Of New Office Building AdditionalAreaOfNewOfficeBuilding	47566	sqft
CY2018Q4	allo	Area Of New Office Building AreaOfNewOfficeBuilding	14943	sqft
CY2018Q4	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P124M
CY2023	allo	Short Term Lease Rent Expense ShortTermLeaseRentExpense	0	usd
CY2018Q4	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P7Y
CY2018Q4	allo	Tenant Improvement Allowance TenantImprovementAllowance	800000	usd
CY2023Q4	us-gaap	Letters Of Credit Outstanding Amount LettersOfCreditOutstandingAmount	6000000	usd
CY2022Q4	us-gaap	Letters Of Credit Outstanding Amount LettersOfCreditOutstandingAmount	6000000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	6775000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	6002000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	88346000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	95122000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	95121000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	101124000	usd
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	12711000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	11664000	usd
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	7513000	usd
CY2023	us-gaap	Variable Lease Cost VariableLeaseCost	3102000	usd
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	2139000	usd
CY2021	us-gaap	Variable Lease Cost VariableLeaseCost	1629000	usd
CY2023	us-gaap	Lease Cost LeaseCost	15813000	usd
CY2022	us-gaap	Lease Cost LeaseCost	13803000	usd
CY2021	us-gaap	Lease Cost LeaseCost	9142000	usd
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	12000000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	12447000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	12627000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	12819000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	13257000	usd
CY2023Q4	allo	Lessee Operating Lease Liability Payments Due Year Five And After Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive	77234000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	128384000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	33263000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	95121000	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0622
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P9Y10D
CY2021	allo	Short Term Lease Rent Expense ShortTermLeaseRentExpense	0	usd
CY2022	allo	Short Term Lease Rent Expense ShortTermLeaseRentExpense	0	usd
CY2022Q4	us-gaap	Asset Retirement Obligation AssetRetirementObligation	600000	usd
CY2023Q4	us-gaap	Asset Retirement Obligation AssetRetirementObligation	600000	usd
CY2023Q4	us-gaap	Purchase Commitment Remaining Minimum Amount Committed PurchaseCommitmentRemainingMinimumAmountCommitted	2100000	usd
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	168642238	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	168642238	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	144438304	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	144438304	shares
CY2023	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0
CY2022	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0
CY2023	allo	Number Of Shares As Percentage Of Common Shares Outstanding NumberOfSharesAsPercentageOfCommonSharesOutstanding	0.05
CY2023Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	6468650	shares
CY2022Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	12932861	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Incremental Compensation Cost ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost	5200000	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	2.57
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	66000000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	83600000	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	80800000	usd
CY2023Q4	us-gaap	Deferred Compensation Share Based Arrangements Liability Current DeferredCompensationShareBasedArrangementsLiabilityCurrent	500000	usd
CY2022Q4	us-gaap	Deferred Compensation Share Based Arrangements Liability Current DeferredCompensationShareBasedArrangementsLiabilityCurrent	1900000	usd
CY2023Q1	allo	Operating Lease Base Rent And Security Deposit Payment OperatingLeaseBaseRentAndSecurityDepositPayment	200000	usd
CY2023Q1	allo	Operating Lease Total Estimated Base Rent OperatingLeaseTotalEstimatedBaseRent	2900000	usd
CY2023	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	2500000	usd
CY2022	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	2300000	usd
CY2021	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	1800000	usd
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-68725000	usd
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-71487000	usd
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-38231000	usd
CY2023	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-21610000	usd
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-40642000	usd
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	8731000	usd
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	11132000	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	8619000	usd
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	4534000	usd
CY2023	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	3873000	usd
CY2022	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	4274000	usd
CY2021	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	2942000	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	82526000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	106111000	usd
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	27889000	usd
CY2023	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	550000	usd
CY2022	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	1673000	usd
CY2021	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	19000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	211124000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	174222000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	144133000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	32826000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	24517000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	15595000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	14524000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	16966000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	14092000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	3039000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	4227000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	3091000	usd
CY2023Q4	allo	Deferred Tax Assets Lease Liabilities DeferredTaxAssetsLeaseLiabilities	26358000	usd
CY2022Q4	allo	Deferred Tax Assets Lease Liabilities DeferredTaxAssetsLeaseLiabilities	28298000	usd
CY2021Q4	allo	Deferred Tax Assets Lease Liabilities DeferredTaxAssetsLeaseLiabilities	15724000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	25350000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	25731000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	14693000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Investments DeferredTaxAssetsInvestments	28735000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Investments DeferredTaxAssetsInvestments	26291000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Investments DeferredTaxAssetsInvestments	15849000	usd
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	73492000	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	41273000	usd
CY2021Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	0	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	2189000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	1741000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	1076000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	417637000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	343266000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	224253000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	0	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	0	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	250000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	81964000	usd
CY2023Q4	allo	Deferred Tax Liabilities Right Of Use Leased DeferredTaxLiabilitiesRightOfUseLeased	17652000	usd
CY2022Q4	allo	Deferred Tax Liabilities Right Of Use Leased DeferredTaxLiabilitiesRightOfUseLeased	23392000	usd
CY2021Q4	allo	Deferred Tax Liabilities Right Of Use Leased DeferredTaxLiabilitiesRightOfUseLeased	12478000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	301000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	244000	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	68000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	17953000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	23636000	usd
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	12796000	usd
CY2023Q4	allo	Deferred Tax Assets Net Of Deferred Tax Liabilities DeferredTaxAssetsNetOfDeferredTaxLiabilities	399684000	usd
CY2022Q4	allo	Deferred Tax Assets Net Of Deferred Tax Liabilities DeferredTaxAssetsNetOfDeferredTaxLiabilities	319630000	usd
CY2021Q4	allo	Deferred Tax Assets Net Of Deferred Tax Liabilities DeferredTaxAssetsNetOfDeferredTaxLiabilities	211457000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	399684000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	319630000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	211457000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	80100000	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	108200000	usd
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	28500000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	0	usd
CY2021	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	0	usd
CY2023	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	0	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	14570000	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	9798000	usd
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	6161000	usd
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	4325000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	4772000	usd
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	3637000	usd
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	usd
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	usd
CY2023	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0	usd
CY2022	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0	usd
CY2021	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0	usd
CY2023	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	0	usd
CY2022	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	0	usd
CY2021	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	0	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	18895000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	14570000	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	9798000	usd
CY2022Q4	us-gaap	Liability For Uncertain Tax Positions Current LiabilityForUncertainTaxPositionsCurrent	0	usd
CY2023Q4	us-gaap	Liability For Uncertain Tax Positions Current LiabilityForUncertainTaxPositionsCurrent	0	usd
CY2021Q4	us-gaap	Liability For Uncertain Tax Positions Current LiabilityForUncertainTaxPositionsCurrent	0	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-327265000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-340414000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-182051000	usd
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	156931778	shares
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	156931778	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	143147165	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	143147165	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	135820386	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	135820386	shares
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.09
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.09
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.38
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.38
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.34
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.34
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	36190861	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	24294136	shares
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	17209986	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	109931000	usd
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	84514000	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	361293000	usd
CY2022Q1	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	364536000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	10241000	usd
CY2022Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	20694000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	481465000	usd
CY2022Q1	us-gaap	Assets Current AssetsCurrent	469744000	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	42788000	usd
CY2022Q1	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	284093000	usd
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	57057000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	109849000	usd
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	120200000	usd
CY2023Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	10292000	usd
CY2022Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	10292000	usd
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	9389000	usd
CY2022Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	9042000	usd
CY2023Q1	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	14381000	usd
CY2022Q1	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	27663000	usd
CY2023Q1	us-gaap	Assets Assets	750128000	usd
CY2022Q1	us-gaap	Assets Assets	978091000	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	14688000	usd
CY2022Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	8708000	usd
CY2023Q1	allo	Accrued And Other Liabilities Current AccruedAndOtherLiabilitiesCurrent	44624000	usd
CY2022Q1	allo	Accrued And Other Liabilities Current AccruedAndOtherLiabilitiesCurrent	27763000	usd
CY2023Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	86000	usd
CY2022Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	147000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	59398000	usd
CY2022Q1	us-gaap	Liabilities Current LiabilitiesCurrent	36618000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	93514000	usd
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	69035000	usd
CY2023Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	5205000	usd
CY2022Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	7171000	usd
CY2023Q1	us-gaap	Liabilities Liabilities	158118000	usd
CY2022Q1	us-gaap	Liabilities Liabilities	112823000	usd
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000	shares
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	145740333	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	145740333	shares
CY2022Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	143569902	shares
CY2022Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	143569902	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	146000	usd
CY2022Q1	us-gaap	Common Stock Value CommonStockValue	143000	usd
CY2023Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1932734000	usd
CY2022Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1847534000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1334936000	usd
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-973161000	usd
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-5934000	usd
CY2022Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-9249000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	592010000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	865267000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	750128000	usd
CY2022Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	978091000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	30000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	39000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	80238000	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	60156000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	18884000	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	19897000	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	99122000	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	80053000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-99092000	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-80014000	usd
CY2023Q1	us-gaap	Interest And Other Income InterestAndOtherIncome	2059000	usd
CY2022Q1	us-gaap	Interest And Other Income InterestAndOtherIncome	492000	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-2935000	usd
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	915000	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-876000	usd
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1407000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-99968000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-78607000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	3992000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-6682000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-95976000	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-85289000	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.69
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.69
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.56
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.56
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	144563829	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	144563829	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	141356306	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	141356306	shares
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-99968000	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-78607000	usd
CY2023Q1	allo	Noncash Collaboration Revenue NoncashCollaborationRevenue	20000	usd
CY2022Q1	allo	Noncash Collaboration Revenue NoncashCollaborationRevenue	26000	usd
CY2023Q1	allo	Gain Loss From Equity Method Investment GainLossFromEquityMethodInvestment	-2935000	usd
CY2022Q1	allo	Gain Loss From Equity Method Investment GainLossFromEquityMethodInvestment	-2535000	usd
CY2023Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-3000	usd
CY2022Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-3000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-626000	usd
CY2022Q1	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-601000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-66639000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-68237000	usd
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	154758000	usd
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	96041000	usd
CY2023Q2	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	337204000	usd
CY2022Q2	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	394451000	usd
CY2023Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	10139000	usd
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	22536000	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	502101000	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	513028000	usd
CY2023Q2	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	52586000	usd
CY2022Q2	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	195637000	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	80314000	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	86837000	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	106386000	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	117216000	usd
CY2023Q2	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	10292000	usd
CY2022Q2	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	10292000	usd
CY2023Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	9382000	usd
CY2022Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	8938000	usd
CY2023Q2	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	11946000	usd
CY2022Q2	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	23673000	usd
CY2023Q2	us-gaap	Assets Assets	773007000	usd
CY2022Q2	us-gaap	Assets Assets	955621000	usd
CY2023Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	10229000	usd
CY2022Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	9713000	usd
CY2023Q2	allo	Accrued And Other Liabilities Current AccruedAndOtherLiabilitiesCurrent	44263000	usd
CY2022Q2	allo	Accrued And Other Liabilities Current AccruedAndOtherLiabilitiesCurrent	34360000	usd
CY2023Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	86000	usd
CY2022Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	104000	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	54578000	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	44177000	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	91821000	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	98232000	usd
CY2023Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	5197000	usd
CY2022Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	6729000	usd
CY2023Q2	us-gaap	Liabilities Liabilities	151596000	usd
CY2022Q2	us-gaap	Liabilities Liabilities	149138000	usd
CY2022Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000	shares
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	167133664	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	167133664	shares
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	143723171	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	143723171	shares
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	167000	usd
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	144000	usd
CY2023Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	2039263000	usd
CY2022Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1871262000	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1414168000	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1053451000	usd
CY2023Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-3851000	usd
CY2022Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-11472000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	621411000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	806483000	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	773007000	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	955621000	usd
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	22000	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	64000	usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	62038000	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	57171000	usd
CY2023Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	18524000	usd
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	19509000	usd
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	80562000	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	76680000	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-80540000	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-76616000	usd
CY2023Q2	us-gaap	Interest And Other Income InterestAndOtherIncome	3778000	usd
CY2022Q2	us-gaap	Interest And Other Income InterestAndOtherIncome	315000	usd
CY2023Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-2470000	usd
CY2022Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-3989000	usd
CY2023Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1308000	usd
CY2022Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3674000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-79232000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-80290000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	2083000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-2223000	usd
CY2023Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-77149000	usd
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-82513000	usd
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.54
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.54
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.56
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.56
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	146795826	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	146795826	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	143385045	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	143385045	shares
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	52000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	103000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	142276000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	117327000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	37408000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	39406000	usd
	us-gaap	Operating Expenses OperatingExpenses	179684000	usd
	us-gaap	Operating Expenses OperatingExpenses	156733000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-179632000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-156630000	usd
	us-gaap	Interest And Other Income InterestAndOtherIncome	5837000	usd
	us-gaap	Interest And Other Income InterestAndOtherIncome	807000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-5405000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-3074000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	432000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2267000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-179200000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-158897000	usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	6075000	usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-8905000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-173125000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-167802000	usd
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.23
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.23
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.12
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	145685993	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	145685993	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	142376280	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	142376280	shares
	us-gaap	Profit Loss ProfitLoss	-179200000	usd
	us-gaap	Profit Loss ProfitLoss	-158897000	usd
	allo	Noncash Collaboration Revenue NoncashCollaborationRevenue	34000	usd
	allo	Noncash Collaboration Revenue NoncashCollaborationRevenue	69000	usd
	allo	Gain Loss From Equity Method Investment GainLossFromEquityMethodInvestment	-5370000	usd
	allo	Gain Loss From Equity Method Investment GainLossFromEquityMethodInvestment	-6525000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-3000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-17000	usd
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-621000	usd
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-1028000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-128496000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-110768000	usd
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	69246000	usd
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	74357000	usd
CY2023Q3	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	396259000	usd
CY2022Q3	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	477872000	usd
CY2023Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7949000	usd
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	16832000	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	473454000	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	569061000	usd
CY2023Q3	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	32170000	usd
CY2022Q3	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	85108000	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	78643000	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	85245000	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	102826000	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	114442000	usd
CY2023Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	10292000	usd
CY2022Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	10292000	usd
CY2023Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	9576000	usd
CY2022Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	9378000	usd
CY2023Q3	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	6450000	usd
CY2022Q3	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	20951000	usd
CY2023Q3	us-gaap	Assets Assets	713411000	usd
CY2022Q3	us-gaap	Assets Assets	894477000	usd
CY2023Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	6205000	usd
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	11045000	usd
CY2023Q3	allo	Accrued And Other Liabilities Current AccruedAndOtherLiabilitiesCurrent	31195000	usd
CY2022Q3	allo	Accrued And Other Liabilities Current AccruedAndOtherLiabilitiesCurrent	36938000	usd
CY2023Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	86000	usd
CY2022Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	99000	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	37486000	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	48082000	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	90102000	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	96706000	usd
CY2023Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	5188000	usd
CY2022Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	6288000	usd
CY2023Q3	us-gaap	Liabilities Liabilities	132776000	usd
CY2022Q3	us-gaap	Liabilities Liabilities	151076000	usd
CY2022Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	143661721	shares
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	74000	usd
CY2023Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000	shares
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	168175221	shares
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	168175221	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	144031588	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	144031588	shares
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	168000	usd
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	144000	usd
CY2023Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	2059333000	usd
CY2022Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1893908000	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1476455000	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1137693000	usd
CY2023Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-2411000	usd
CY2022Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-12958000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	580635000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	743401000	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	713411000	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	894477000	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	22000	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	27000	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	45977000	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	63641000	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	17041000	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	18897000	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	63018000	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	82538000	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-62996000	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-82511000	usd
CY2023Q3	us-gaap	Interest And Other Income InterestAndOtherIncome	6205000	usd
CY2022Q3	us-gaap	Interest And Other Income InterestAndOtherIncome	1002000	usd
CY2023Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-5496000	usd
CY2022Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-2733000	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	709000	usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1731000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-62287000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-84242000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	1440000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-1486000	usd
CY2023Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-60847000	usd
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-85728000	usd
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.37
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.37
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.59
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.59
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	167649010	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	167649010	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	143661721	shares
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	130000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	188253000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	180968000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	54449000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	58303000	usd
	us-gaap	Operating Expenses OperatingExpenses	242702000	usd
	us-gaap	Operating Expenses OperatingExpenses	239271000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-242628000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-239141000	usd
	us-gaap	Interest And Other Income InterestAndOtherIncome	12042000	usd
	us-gaap	Interest And Other Income InterestAndOtherIncome	1809000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-10901000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-5807000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1141000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3998000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-241487000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-243139000	usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	7515000	usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-10391000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-233972000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-253530000	usd
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.58
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.58
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.70
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.70
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	153087449	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	153087449	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	142809469	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	142809469	shares
	us-gaap	Profit Loss ProfitLoss	-241487000	usd
	us-gaap	Profit Loss ProfitLoss	-243139000	usd
	allo	Noncash Collaboration Revenue NoncashCollaborationRevenue	49000	usd
	allo	Noncash Collaboration Revenue NoncashCollaborationRevenue	87000	usd
	allo	Gain Loss From Equity Method Investment GainLossFromEquityMethodInvestment	-10866000	usd
	allo	Gain Loss From Equity Method Investment GainLossFromEquityMethodInvestment	-9247000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-3000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-19000	usd
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-615000	usd
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-1454000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-184026000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-158423000	usd

Files In Submission

Name	View Source	Status
0001737287-24-000021-index-headers.html	Edgar Link	pending
0001737287-24-000021-index.html	Edgar Link	pending
0001737287-24-000021.txt	Edgar Link	pending
0001737287-24-000021-xbrl.zip	Edgar Link	pending
allo-20231231.htm	Edgar Link	pending
allo-20231231.xsd	Edgar Link	pending
allo-20231231xex1010.htm	Edgar Link	pending
allo-20231231xex1018.htm	Edgar Link	pending
allo-20231231xex1030.htm	Edgar Link	pending
allo-20231231xex107.htm	Edgar Link	pending
allo-20231231xex231.htm	Edgar Link	pending
allo-20231231xex311.htm	Edgar Link	pending
allo-20231231xex312.htm	Edgar Link	pending
allo-20231231xex321.htm	Edgar Link	pending
allo-20231231xex322.htm	Edgar Link	pending
allo-20231231xex971.htm	Edgar Link	pending
allo-20231231_g1.jpg	Edgar Link	pending
allo-20231231_g2.jpg	Edgar Link	pending
allo-20231231_g3.jpg	Edgar Link	pending
allo-20231231_g4.jpg	Edgar Link	pending
allo-20231231_g5.jpg	Edgar Link	pending
allo-20231231_g6.jpg	Edgar Link	pending
allo-20231231_g7.jpg	Edgar Link	pending
allo-20231231_g8.jpg	Edgar Link	pending
allo-20231231_g9.jpg	Edgar Link	pending
allogenelogo.jpg	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
allo-20231231_lab.xml	Edgar Link	unprocessable
allo-20231231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
allo-20231231_htm.xml	Edgar Link	completed
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
allo-20231231_cal.xml	Edgar Link	unprocessable
allo-20231231_def.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ALLO
Allogene Therapeutics, Inc. Stock $allo

2024 Q1 Form 10-K Financial Statement

#000173728724000021 Filed on March 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ALLO Allogene Therapeutics, Inc. Stock $allo

2024 Q1 Form 10-K Financial Statement

#000173728724000021 Filed on March 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ALLO
Allogene Therapeutics, Inc. Stock $allo